Preclinical Evaluation of a Trop2-Targeted Peptide Probe for PET Imaging of Triple-Negative Breast Cancer
Analytical Chemistry · 28.10.2025 · 97 (42) · 23598-23608
DOI: 10.1021/acs.analchem.5c05242 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical Chemistry, online erschienen am 17.10.2025. Verfasst von Yuan Zha und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Health Commission Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Med…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Antigens, Neoplasm, Cell Adhesion Molecules, Positron-Emission Tomography. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Wuxi Science and Technology Association, Natural Science Foundation of Jiangsu Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Trophoblast cell surface antigen 2 (Trop2) has been extensively characterized as a clinically relevant pan-cancer biomarker that is overexpressed in multiple malignancies, including triple-negative breast cancer (TNBC). In this study, we employed computational simulation strategies to develop peptide WP8 derived from midkine (MDK), a particular ligand of Trop2, and designed a Trop2-targeting radiotracer [68Ga]Ga-NOTA-PEG2-WP8 for positron emission tomography (PET) imaging of Trop2 expression. This radiotracer exhibits nanomolar affinity for Trop2, along with favorable stability and pharmacokinetic properties. Dynamic PET imaging revealed that [68Ga]Ga-NOTA-PEG2-WP8 displays significant and specific uptake in Trop2-positive TNBC tissues, enabling rapid and precise identification of Trop2 expression. Notably, this radiotracer demonstrated high sensitivity in detecting the response of TNBC tumor to Trop2-targeting antibody-drug conjugates (ADCs). Collectively, these findings indicate that the peptide-based radiotracer [68Ga]Ga-NOTA-PEG2-WP8 holds considerable potential as a noninvasive tool for accurately monitoring of Trop2 expression before, during, and after ADC-based therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Health Commission Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu 214063, China.
- Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China.
- Department of Pharmacy, Affiliated Women's Hospital of Jiangnan University, Wuxi Maternity and Child Health Care Hospital, Wuxi, Jiangsu 214002, China.
- Affiliated Women's Hospital of Jiangnan University, Jiangnan University, Wuxi, Jiangsu 214002, China.
Förderung
- Wuxi Science and Technology Association
- Natural Science Foundation of Jiangsu Province
- National Natural Science Foundation of China
- Jiangsu Commission of Health
- Wuxi Science and Technology Development fund
- Wuxi Municipal Health Commission
- Jiangsu Administration of Traditional Chinese Medicine
- Jiangsu Province Capability Improvement Project through Science, Technology and Education
Zitieren
APA
Zha, Y., Zhu, X., Xue, Y., Huang, Z., Wang, S., Jiao, Y., Chen, Y., Yao, Y., Wang, K., & Fang, J. (2025). Preclinical Evaluation of a Trop2-Targeted Peptide Probe for PET Imaging of Triple-Negative Breast Cancer. Analytical Chemistry, 97(42), 23598-23608. https://doi.org/10.1021/acs.analchem.5c05242
Vancouver
Zha Y, Zhu X, Xue Y, Huang Z, Wang S, Jiao Y, et al. Preclinical Evaluation of a Trop2-Targeted Peptide Probe for PET Imaging of Triple-Negative Breast Cancer. Analytical Chemistry. 2025;97(42):23598-23608. doi:10.1021/acs.analchem.5c05242
BibTeX
@article{Zha2025,
author = {Zha, Yuan and Zhu, Xue and Xue, Yan and Huang, Zhihong and Wang, Shuang and Jiao, Yang and Chen, Yu and Yao, Ying and Wang, Ke and Fang, Jing},
title = {Preclinical Evaluation of a Trop2-Targeted Peptide Probe for PET Imaging of Triple-Negative Breast Cancer},
journal = {Analytical Chemistry},
year = {2025},
volume = {97},
number = {42},
pages = {23598--23608},
doi = {10.1021/acs.analchem.5c05242}
}
EUVIMED